Accommodation: Does it apply to human leukocyte antigens?

Transplantation

Volumn 93, Issue 3, 2012, Pages 244-246

  Rose, Marlene L ^a   West, Lori J ^b  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ABO incompatibility; Accommodation; Antibody mediated rejection

Indexed keywords

ANTIGEN; CARBOHYDRATE ANTIGEN; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; BLOOD GROUP ABO INCOMPATIBILITY; GENE EXPRESSION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOADSORPTION; KIDNEY TRANSPLANTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; UPREGULATION;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION;

EID: 84856450519     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823f468c     Document Type: Review

References (26)

1. Chopek MW, Simmons RL, Platt JL. ABO-incompatible kidney transplantation: Initial immunopathologic evaluation. Transplant Proc 1987; 19: 4553.
2. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: A review of progress. Immunol Today 1990; 11: 450.
3. Bach FH, Turman MA, Vercellotti GM, et al. Accommodation:Aworking paradigm for progressing toward clinical discordant xenografting. Transplant Proc 1991; 23: 205.
4. Bach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: Expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196.
5. Stussi G, West L, Cooper DK, et al. ABO-incompatible allotransplantation as a basis for clinical xenotransplantation. Xenotransplantation 2006; 13: 390.
6. Fan X, Ang A, Pollock-Barziv SM, et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004; 10: 1227.
7. West LJ. ABO-incompatible hearts for infant transplantation. Curr Opin Organ Transplant 2011; 16: 548.
8. Dipchand AI, Pollock BarZiv SM, Manlhiot C, et al. Equivalent outcomes for pediatric heart transplantation recipients: ABO-blood group incompatible versus ABO-compatible. Am J Transplant 2010; 10: 389.
9. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009; 87: 1246.
10. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: Integrating paired donation into desensitization protocols. Am J Transplant 2010; 10: 449.
11. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009; 9: 536.
12. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodies-a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
13. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371.
14. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
15. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829.
16. Ding JW, Zhou T, Ma L, et al. Expression of complement regulatory proteins in accommodated xenografts induced by anti-alpha-Gal IgG1 in a rat-to-mouse model. Am J Transplant 2008; 8: 32.
17. Chen SS, Zhong S, Xiang Y, et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 2011; 11: 2057.
18. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
19. Higgins R, Lowe D, Hathaway M, et al. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. Transplantation 2009; 87: 882.
20. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857.
21. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312.
22. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
23. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 2004; 4: 438.
24. Stastny P, Lavingia B, Fixler DE, et al. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation 2007; 84: 738.
25. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.
26. Dijke IE, Weimar W, Baan CC. Regulatory T cells after organ transplantation: Where does their action take place? Hum Immunol 2008 69 389